What's Happening?
Verastem Oncology has announced the discontinuation of its RAMP 203 Phase 1/2 clinical trial for advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC). The decision follows an evaluation of interim
data and reflects a strategic shift to prioritize the development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor. The RAMP 203 trial, conducted in collaboration with Amgen, evaluated avutometinib and LUMAKRAS™ in combination with defactinib. Despite showing early anti-tumor responses, the trial was halted due to the emergence of next-generation G12C inhibitors with higher response rates. Verastem will now focus on VS-7375, which has shown a 69% response rate in advanced KRAS G12D NSCLC. The company will also continue its RAMP 205 trial, which evaluates avutometinib and defactinib in combination with chemotherapy for metastatic pancreatic cancer.
Why It's Important?
The discontinuation of the RAMP 203 trial marks a significant pivot in Verastem's strategy, highlighting the competitive and rapidly evolving landscape of cancer treatment. By focusing on the KRAS G12D inhibitor, Verastem aims to address a critical need in oncology, as KRAS mutations are prevalent in various cancers and have been challenging to target effectively. The decision underscores the importance of adapting to new scientific insights and competitive pressures in the biopharmaceutical industry. This shift could potentially lead to more effective treatments for patients with advanced lung cancer and other solid tumors, offering hope for improved outcomes in a field where treatment options are limited.
What's Next?
Verastem will continue to develop VS-7375 and assess opportunities to share data from the RAMP 203 trial. The company is also conducting the RAMP 301 trial, a Phase 3 study evaluating avutometinib and defactinib for recurrent low-grade serous ovarian cancer. These efforts are part of Verastem's broader strategy to develop novel therapies for RAS/MAPK pathway-driven cancers. The outcomes of these trials will be closely watched by the medical community and investors, as they could influence future treatment protocols and Verastem's market position.
